Cargando…

siRNA Targeting and Treatment of Gastrointestinal Diseases

RNA interference via small interfering RNA (siRNA) offers opportunities to precisely target genes that contribute to gastrointestinal (GI) pathologies, such as inflammatory bowel disease, celiac, and esophageal scarring. Delivering the siRNA to the GI tract proves challenging as the harsh environmen...

Descripción completa

Detalles Bibliográficos
Autor principal: Chevalier, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853152/
https://www.ncbi.nlm.nih.gov/pubmed/31309709
http://dx.doi.org/10.1111/cts.12668
_version_ 1783469988775985152
author Chevalier, Rachel
author_facet Chevalier, Rachel
author_sort Chevalier, Rachel
collection PubMed
description RNA interference via small interfering RNA (siRNA) offers opportunities to precisely target genes that contribute to gastrointestinal (GI) pathologies, such as inflammatory bowel disease, celiac, and esophageal scarring. Delivering the siRNA to the GI tract proves challenging as the harsh environment of the intestines degrades the siRNA before it can reach its target or blocks its entry into its site of action in the cytoplasm. Additionally, the GI tract is large and disease is often localized to a specific site. This review discusses polymer and lipid‐based delivery systems for protection and targeting of siRNA therapies to the GI tract to treat local disease.
format Online
Article
Text
id pubmed-6853152
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68531522019-12-16 siRNA Targeting and Treatment of Gastrointestinal Diseases Chevalier, Rachel Clin Transl Sci Reviews RNA interference via small interfering RNA (siRNA) offers opportunities to precisely target genes that contribute to gastrointestinal (GI) pathologies, such as inflammatory bowel disease, celiac, and esophageal scarring. Delivering the siRNA to the GI tract proves challenging as the harsh environment of the intestines degrades the siRNA before it can reach its target or blocks its entry into its site of action in the cytoplasm. Additionally, the GI tract is large and disease is often localized to a specific site. This review discusses polymer and lipid‐based delivery systems for protection and targeting of siRNA therapies to the GI tract to treat local disease. John Wiley and Sons Inc. 2019-08-05 2019-11 /pmc/articles/PMC6853152/ /pubmed/31309709 http://dx.doi.org/10.1111/cts.12668 Text en © 2019 The Author. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Reviews
Chevalier, Rachel
siRNA Targeting and Treatment of Gastrointestinal Diseases
title siRNA Targeting and Treatment of Gastrointestinal Diseases
title_full siRNA Targeting and Treatment of Gastrointestinal Diseases
title_fullStr siRNA Targeting and Treatment of Gastrointestinal Diseases
title_full_unstemmed siRNA Targeting and Treatment of Gastrointestinal Diseases
title_short siRNA Targeting and Treatment of Gastrointestinal Diseases
title_sort sirna targeting and treatment of gastrointestinal diseases
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853152/
https://www.ncbi.nlm.nih.gov/pubmed/31309709
http://dx.doi.org/10.1111/cts.12668
work_keys_str_mv AT chevalierrachel sirnatargetingandtreatmentofgastrointestinaldiseases